Matches 1 - 50 out of 197 1 2 3 4 >


Match Document Document Title
US20150110718 METHODS AND KITS FOR DETERMINING A PLACEBO PROFILE IN SUBJECTS FOR CLINICAL TRIALS AND FOR TREATMENT OF PATIENTS  
The present invention is directed to methods and assays for identifying subjects participating in clinical trials that may exhibit a placebo response and identifying treatments for subjects with...
US20100310599 Orally Bioavailable Lipid-Based Constructs  
The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.
US20120196894 NOVEL TRPA1 ANTAGONISTS  
The present invention relates to compositions and methods that modulate at least one TRP family member. Specifically, the present invention relates to novel TRPA1 antagonists and their use in the...
US20110130466 USE OF RASAGILINE FOR THE TREATMENT OF PROGRESSIVE SUPRANUCLEAR PALSY  
A method for the treatment of Progressive Supranuclear Palsy. Such method includes administering to a subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof.
US20140170208 TRANSDERMAL PATCH FORMULATION  
A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to...
US20120265158 Transdermal Patch Formulation  
A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to...
US20120029087 USE OF RASAGILINE FOR THE TREATMENT OF OLFACTORY DYSFUNCTION  
Disclosed are methods of treating olfactory dysfunction by periodically administering a therapeutically effective amount of rasagiline or a pharmaceutically acceptable salt of rasagiline to a subject.
US20130197091 USE OF ADRENERGIC BETA-E-RECEPTOR BLOCKERS IN CANCER TREATMENT  
A method for treating an cancer disease is disclosed comprising administering to a subject a pharmaceutical composition comprising an adrenergic beta-3-receptor blocker.
US20140336187 METHODS FOR TREATING LEISHMANIASIS  
Methods are provided to inhibit proliferation of Leishmania parasites, and in particular Leshmania donovani with imido-substituted 1,4-naphthoquinones, including novel compounds. Administering an...
US20140155369 PREVENTIVES/REMEDIES FOR STRESS URINARY INCONTINENCE AND METHOD OF SCREENING THE SAME  
An agent for the prophylaxis or treatment of stress urinary incontinence, which contains a substance that activates a serotonin 5-HT2C receptor, an agent for the prophylaxis or treatment of stress...
US20110224256 THERAPEUTIC IMPRINTING FOR THE TREATMENT OF PSYCHIATRIC DISORDERS  
The invention features methods, kits, and compositions for the treatment of psychiatric disorders using therapeutic imprinting in pre-pubescent subjects.
US20080146622 Use Of Substituted 2-Aminotetralins For Preventive Treatment Of Parkinson's Disease  
The invention relates to the use of substituted 2-aminotetralins of general formula (I) as a medicament for the preventive treatment of Parkinson's disease.
US20060165814 Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia  
Combinations comprising vanadium (IV)/(V) compounds and pharmaceutically acceptable amines are provided. Combinations thereof are provided for the treatment or prevention of dyslipidemia,...
US20110110871 SUBSTITUTED 3-(PHENOXYMETHYL) BENZYL AMINES AND PERSONAL CARE COMPOSITIONS  
Certain novel substituted 3-(phenoxymethyl) benzyl amines and personal care compositions comprising such, which are particularly beneficial for skin lightening and achieving evenness of color,...
US20120022070 Heat Shock Protein 90 Inhibitors, Methods Of Preparing Same, And Methods For Their Use  
Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors are disclosed. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases and...
US20140051767 PARENTERAL FORMULATIONS OF RASAGILINE  
This application provides a method of preferentially inhibiting monoamine oxidase A (MAOA) in the brain of a subject relative to in the intestine of the subject comprising parenterally...
US20120149693 THERAPEUTIC COMPOUNDS  
The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for...
US20140121284 Stable Pharmaceutical Composition  
Provided is a stable pharmaceutical composition having as an active ingredient a therapeutically effective amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptable salt thereof, an...
US20120108570 Pharmacological Treatment for Sleep Apnea  
The present invention relates generally to pharmacological methods for the prevention of amelioration of sleep-related breathing disorders via administration of agents or combinations of agents...
US20120129775 ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE  
Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or...
US20130302441 METHODS FOR THE TREATMENT OF SKIN NEOPLASMS  
Methods of treating skin neoplasms using a monoamine oxidase inhibitor, e.g., a propynylaminoindan (such as rasagiline) are provided. Pharmaceutical compositions and kits comprising monoamine...
US20140323581 TRANSCRIPTOME WIRING ANALYSIS IN PARKINSON'S DISEASE AND USES THEREOF  
The invention is directed to methods to identify predisposition or risk to develop Parkinson's disease, methods to identify agents which have therapeutic effect on Parkinson's disease, and methods...
US20120263789 DELAYED RELEASE RASAGILINE FORMULATION  
Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.
US20120100189 DELAYED RELEASE RASAGILINE MALATE FORMULATION  
Disclosed are formulations which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties.
US20090318564 Process for preparing and drying solid rasagiline base  
Disclosed is crystalline R(+)-N-propargyl-l-aminoindan containing water at an amount of less than 0.5% by weight and a pharmaceutical composition comprising the same, and the process for the...
US20120003310 DELAYED RELEASE RASAGILINE FORMULATION  
Disclosed are formulations of rasagiline base which are designed to delay release of rasagiline while maintaining specific pharmacokinetic properties. Also, disclosed are rasagiline citrate salt...
US20140051768 METHOD OF TREATING DISEASES THAT RESPOND TO THERAPY BY DOPAMINE OR DOPAMINE AGONISTS  
The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable...
US20070197480 (S)-2-N-Propylamino-5-Hydroxytetralin As A D3-Agonist  
The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable...
US20150252438 AGENTS FOR REVERSING EPIGENETIC SILENCING OF GENES  
The present invention provides methods for discovering agents that are effective in reversing epigenetic silencing by inhibiting the interaction of methyl-binding (MBD) proteins with methylated...
US20140194510 DISPERSIONS OF RASAGILINE CITRATE  
The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
US20120059058 DISPERSIONS OF RASAGILINE CITRATE  
The subject invention provides a solid dispersion of rasagiline citrate, a composition and a process for the manufacture thereof.
US20140128474 TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-1-NAPTHALENAMINE  
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed....
US20130158125 Treatment of CNS Disorders with trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine  
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed....
US20120136065 Treatment of CNS Disorders with trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine  
Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed....
US20150030539 COMPOUNDS FOR USE IN IMAGING, DIAGNOSING AND/OR TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM OR OF TUMORS  
This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such...
US20120095107 METHODS FOR TREATMENT OF CARDIOVASCULAR DISORDERS AND DISEASES  
Propargylamine, propargylamine derivatives including N-propargyl-l-aminoindan, enantiomers and analogs thereof, and pharmaceutically acceptable salts thereof, are useful for prevention or...
US20120095048 ALLOSTERIC BINDING COMPOUNDS  
The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment...
US20110263719 POLYMORPHIC FORM OF RASAGILINE MESYLATE  
The present invention relates to a novel crystalline form of rasagiline mesylate and a pure form of rasagiline mesylate and processes for their preparation. Further, the invention relates to...
US20150202169 NOVEL REGULATORS OF ALDEHYDE DEHYDROGENASE ALDH3A1 AND RELATED THERAPEUTIC METHODS  
Described herein are compositions and methods for the treatment of cancer, and in particular cancers characterized by a high level of ALD3H1 activity, which is associated with chemoresistance to...
US20090312436 Rasagiline for parkinson's disease modification  
A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable...
US20060116350 Dopamine 3 receptor agonist and antagonist treatment of gastrointestinal motility disorders  
The invention discloses that systemic activation of dopamine 3 receptor (D3R) significantly delays gastric emptying in rat, suggesting that D3R plays an important role in the regulation of gastric...
US20140243418 RASAGILINE FOR PARKINSON'S DISEASE MODIFICATION  
A method for modifying Parkinson's disease by periodically administering a pharmaceutical composition comprising a therapeutically effective amount of rasagiline or a pharmaceutically acceptable...
US20080003275 Treatment of Premature Ejaculation  
The invention relates to methods and compositions for treating premature ejaculation in a male or prolonging intercourse comprising administering to the male an antidepressant via a route selected...
US20140364506 DEUTERIUM ENRICHED RASAGILINE  
The subject invention provides deuterated rasagiline, its salts and uses.
US20120101168 DEUTERIUM ENRICHED RASAGILINE  
The subject invention provides deuterated rasagiline, its salts and uses.
US20090062400 Method of treating glaucoma using rasagiline  
Disclosed is a method of reducing glaucoma in a subject afflicted with glaucoma, comprising administering to the subject an amount of R(+)-N-propargyl-1-aminoindan or a pharmaceutically acceptably...
US20110067123 MAO-B ELEVATION AS AN EARLY PARKINSON'S DISEASE BIOMARKER  
This invention pertains to development of a new animal model for Parkinson's Disease (PD) and to the discovery that elevated monoamine oxygenase B (MOA-B) expression and/or activity is a strong...
US20090111892 Rasagiline Orally Disintegrating Compositions  
This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at...
US20090062399 DEUTERIUM-ENRICHED SERTRALINE  
The present application describes deuterium-enriched sertraline, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.
US20120196852 INHIBITORS OF METHIONINE AMINOPEPTIDASES AND METHODS OF TREATING DISORDERS  
The invention is directed towards novel naphthoquinone and naphthothiazole compounds, and methods of treating disorders related to MetAP, including tuberculosis and bacterial infection, using...

Matches 1 - 50 out of 197 1 2 3 4 >